Inhibitor Therapeutics Announces Clinical Update on Itraconazole Program

What Happened

• Inhibitor Therapeutics, Inc. (INTI) issued a press release dated March 31, 2026 titled “Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome.”
• The press release was furnished as Exhibit 99.1 to a Form 8‑K filed with the SEC on April 1, 2026.

Key Details

• Press release date: March 31, 2026.
• Form 8‑K filing date: April 1, 2026; press release attached as Exhibit 99.1.
• Subject: clinical, formulation and intellectual property (IP) developments for the company’s itraconazole program.
• Indication noted: Gorlin Syndrome (a rare genetic condition).

Why It Matters

• The company publicly communicated progress across clinical, formulation and IP areas for a development program, which is material to assessing the program’s development status and intellectual property position.
• For investors, such updates can affect how you view program risk and timing; the filing itself does not report financial results or executive changes — it simply makes the company’s program update available to the market.
• Investors should read the attached press release (Exhibit 99.1) for the full details of the clinical, formulation and IP information disclosed.